Recent clinical trials of immunotherapy in non-small-cell lung cancer

被引：7
|
作者：
Gkolfinopoulos, Stavros [1 ]
Mountzios, Giannis [2 ]
机构：
[1] BOC Oncol Ctr, Med Oncol Dept, CY-2006 Nicosia, Cyprus
[2] Henry Dunant Hosp Ctr, Med Oncol Dept 2, Athens 11526, Greece
来源：
IMMUNOTHERAPY | 2019年 / 11卷 / 06期
关键词：
atezolizumab; avelumab; checkpoint inhibitors; durvalumab; ipilimumab; nivolumab; non-small-cell lung cancer; pembrolizumab; DOCETAXEL; NIVOLUMAB; INTERLEUKIN-2; ATEZOLIZUMAB; BURDEN;
D O I：
10.2217/imt-2019-0021
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：461 / 466
页数：6
相关论文
共 50 条
  • [41] Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity
    Rossi, Sabrina
    Castello, Angelo
    Toschi, Luca
    Lopci, Egesta
    IMMUNOTHERAPY, 2018, 10 (09) : 797 - 805
  • [42] Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer
    Du, Wei
    Chen, Chen
    Lin-feng Luo
    Li-na He
    Wang, Yixing
    Zhang, Xuanye
    Zhou, Yixin
    Lin, Zuan
    Hong, Shaodong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 1103 - 1113
  • [43] Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer
    Rizvi, Naiyer A.
    Peters, Solange
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1986 - 1988
  • [44] Challenges of Immunotherapy in Stage IV Non-Small-Cell Lung Cancer
    Stock-Martineau, Sophie
    Magner, Kate
    Jao, Kevin
    Wheatley-Price, Paul
    JCO ONCOLOGY PRACTICE, 2021, 17 (08) : 465 - +
  • [45] The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly
    Sgambato, Assunta
    Casaluce, Francesca
    Gridelli, Cesare
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (05) : 565 - 571
  • [46] Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets
    Sham, Nelson Ow
    Zhao, Lei
    Zhu, Ziwen
    Roy, Tanner M.
    Xiao, Huaping
    Bai, Qian
    Wakefield, Mark R.
    Fang, Yujiang
    ANTICANCER RESEARCH, 2022, 42 (07) : 3275 - 3284
  • [47] Immunotherapy for non-small-cell lung cancer: the past 10 years
    Vansteenkiste, Johan
    Craps, Julie
    De Brucker, Nele
    Wauters, Isabelle
    FUTURE ONCOLOGY, 2015, 11 (19) : 2681 - 2695
  • [48] Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice
    Califano, Raffaele
    Lal, Rohit
    Lewanski, Conrad
    Nicolson, Marianne C.
    Ottensmeier, Christian H.
    Popat, Sanjay
    Hodgson, Matthew
    Postmus, Pieter E.
    FUTURE ONCOLOGY, 2018, 14 (23) : 2415 - 2431
  • [49] Immunotherapy in previously treated non-small cell lung cancer (NSCLC)
    Leal, Ticiana A.
    Ramalingam, Suresh S.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S422 - S432
  • [50] Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer
    Califano, Raffaele
    Kerr, Keith
    Morgan, Robert David
    Lo Russo, Giuseppe
    Garassino, Marina
    Morgillo, Floriana
    Rossi, Antonio
    CURRENT ONCOLOGY REPORTS, 2016, 18 (09)
12345